Adlai Nortye Ltd.

ANL | NASDAQ

Price Alert Chart Builder DCF Calculator

$15.57

-$0.17 (-1.08%)

At close: Sep 21, 2026, 4:00 PM ET

$15.57

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.08%

(1D)

Rating

Updated: Aug 26, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $826.46M

1D Range

15.41 16.11

52W Range

0.88 17.25

Valuation (TTM)

PE -7.98

PB 3.85

EV/EBITDA -28.94

Valuation (NTM)

Forward PE 5.06

Forward PEG -0.14

Price Target $33

Cash Flow

FCF Yield -7.0%

SBC Adj. FCF Yield -7.3%

SBC Impact -3.9%

Margins

Gross Margin 100.0%

Operating Margin -113.3%

FCF Margin -296.0%

Growth (CAGR)

Revenue 3Y | 5Y 112.8% | -80.3%

Dil EPS 3Y | 5Y 79.9% | 11.7%

FCF 3Y | 5Y -17.6% | -17.4%

Returns

ROA -9.1%

ROE -21.8%

ROIC -9.2%

Financial Health

Net Cash

$206.93M

Current Ratio 9.55

Interest Coverage -16.99

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide ...

Sector Healthcare

Industry Biotechnology

Employees 109

IPO Date Sep 28, 2023

Website www.adlainortye.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Mar 3, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$31.50

Upside

+102.31%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞